Valeo Pharma Inc. News
Valeo Pharma to Present at the 2022 Bloom Burton & Co Healthcare Investor Conference
April 25, 2022 (Source) – Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]
Valeo Pharma Announces Listing of Convertible Debentures on TSX
April 19, 2022 (Source) – Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]
Valeo Pharma Announces Listing to the Toronto Stock Exchange
The Company’s shares and warrants to start trading on March 29th, 2022 March 28, 2022 (Source) — Valeo Pharma Inc. (TSX: VPH) (OTCQB: […]
Valeo Pharma Reports Its First Quarter 2022 Results and Highlights
Q1-22 revenues of $4.2 million, up 128% over Q1-21 Q1-22 gross margins of $1.4 million, up 266% over Q1-21 Public reimbursement secured […]
Valeo Pharma Secures Additional Public Reimbursement for Redesca™, Enerzair® Breezhaler® and Atectura® Breezhaler®
Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia Enerzair Breezhaler and Atectura Breezhaler reimbursement also […]
Valeo Pharma to Host First Quarter 2022 Results Conference Call / Webcast and Attend the 8th Annual AlphaNorth Capital Conference
March 17, 2022 (Source) – Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical […]
